<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37161609</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses.</ArticleTitle><Pagination><StartPage>4292</StartPage><EndPage>4305</EndPage><MedlinePgn>4292-4305</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad155</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health emergency. Although SARS-CoV-2 is primarily a respiratory pathogen, extra-respiratory organs, including the CNS, can also be affected. Neurologic symptoms have been observed not only during acute SARS-CoV-2 infection, but also at distance from respiratory disease, also known as long-COVID or neurological post-acute sequelae of COVID-19 (neuroPASC). The pathogenesis of neuroPASC is not well understood, but hypotheses include SARS-CoV-2-induced immune dysfunctions, hormonal dysregulations and persistence of SARS-CoV-2 reservoirs. In this prospective cohort study, we used a high throughput systems serology approach to dissect the humoral response to SARS-CoV-2 (and other common coronaviruses: 229E, HKU1, NL63 and OC43) in the serum and CSF from 112 infected individuals who developed (n = 18) or did not develop (n = 94) neuroPASC. Unique SARS-CoV-2 humoral profiles were observed in the CSF of neuroPASC compared with serum responses. All antibody isotypes (IgG, IgM, IgA) and subclasses (IgA1-2, IgG1-4) were detected in serum, whereas CSF was characterized by focused IgG1 (and absence of IgM). These data argue in favour of compartmentalized brain-specific responses against SARS-CoV-2 through selective transfer of antibodies from the serum to the CSF across the blood-brain barrier, rather than intrathecal synthesis, where more diversity in antibody classes/subclasses would be expected. Compared to individuals who did not develop post-acute complications following infection, individuals with neuroPASC had similar demographic features (median age 65 versus 66.5 years, respectively, P = 0.55; females 33% versus 44%, P = 0.52) but exhibited attenuated systemic antibody responses against SARS-CoV-2, characterized by decreased capacity to activate antibody-dependent complement deposition (ADCD), NK cell activation (ADNKA) and to bind Fc&#x3b3; receptors. However, surprisingly, neuroPASC individuals showed significantly expanded antibody responses to other common coronaviruses, including 229E, HKU1, NL63 and OC43. This biased humoral activation across coronaviruses was particularly enriched in neuroPASC individuals with poor outcome, suggesting an 'original antigenic sin' (or immunologic imprinting), where pre-existing immune responses against related viruses shape the response to the current infection, as a key prognostic marker of neuroPASC disease. Overall, these findings point to a pathogenic role for compromised anti-SARS-CoV-2 responses in the CSF, likely resulting in incomplete virus clearance from the brain and persistent neuroinflammation, in the development of post-acute neurologic complications of SARS-CoV-2 infection.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spatola</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2548-0429</Identifier><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nziza</LastName><ForeName>Nad&#xe8;ge</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Wonyeong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yixiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Dansu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinoto</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3249-4792</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37131 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozzetti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37131 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiodega</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37131 Verona, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology/Stroke Unit, San Maurizio Hospital, 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37131 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauffenburger</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-0050-989X</Identifier><AffiliationInfo><Affiliation>Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariotto</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, 37131 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>Galit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT and Harvard Medical School, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI135995</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AR078938</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AR073334</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR072577</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI146785</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS122570</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070253</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR077607</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI080289</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 CA260476</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2023 Oct 3;146(10):3960-3962. doi: 10.1093/brain/awad307</RefSource><PMID Version="1">37681523</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody-mediated complement activation</Keyword><Keyword MajorTopicYN="N">fc receptor</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword></KeywordList><CoiStatement>S.M. received speaker honoraria from Novartis and Biogen. G.A. is a founder of SeromYx Systems, Inc. and is a member of the scientific advisory board of Sanofi Pasteur. The other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37161609</ArticleId><ArticleId IdType="pmc">PMC11004923</ArticleId><ArticleId IdType="doi">10.1093/brain/awad155</ArticleId><ArticleId IdType="pii">7158783</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu &#xa0;Z, Shi &#xa0;L, Wang &#xa0;Y, et al. &#xa0;Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai &#xa0;C-C, Shih &#xa0;T-P, Ko &#xa0;W-C, et al. &#xa0;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta &#xa0;EM, Batra &#xa0;A, Clark &#xa0;JR, et al. &#xa0;Frequent neurologic manifestations and encephalopathy-associated morbidity in COVID-19 patients. Ann Clin Transl Neurol. 2020;7:2221&#x2013;2230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik &#xa0;IJ, Tyler &#xa0;KL. COVID-19: a global threat to the nervous system. Ann Neurol. 2020;88:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Harapan &#xa0;BN, Yoo &#xa0;HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268:3059&#x2013;3071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826147</ArticleId><ArticleId IdType="pubmed">33486564</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich &#xa0;S, Nath &#xa0;A. Nervous system consequences of COVID-19. Science. 2022;375:267&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson &#xa0;BA, Visvabharathy &#xa0;L, Ali &#xa0;ST, et al. &#xa0;Plasma biomarkers of neuropathogenesis in hospitalized patients with COVID-19 and those with postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflammation. 2022;9:e1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901169</ArticleId><ArticleId IdType="pubmed">35256481</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi &#xa0;N, Di Napoli &#xa0;M, Biller &#xa0;J, et al. &#xa0;The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection. Curr Neurol Neurosci Rep. 2021;21:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237541</ArticleId><ArticleId IdType="pubmed">34181102</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal &#xa0;AD, VanElzakker &#xa0;MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke &#xa0;J, L&#xfc;tgehetmann &#xa0;M, Hagel &#xa0;C, et al. &#xa0;Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj &#xa0;A, Thomas &#xa0;N, Ellul &#xa0;MA, et al. &#xa0;Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7:875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee &#xa0;M-H, Perl &#xa0;DP, Nair &#xa0;G, et al. &#xa0;Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 2021;384:481&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787217</ArticleId><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussman &#xa0;JP. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol. 2020;11:1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406916</ArticleId><ArticleId IdType="pubmed">32848776</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotti &#xa0;FM, Menchinelli &#xa0;G, Marchetti &#xa0;S, et al. &#xa0;Assessment of SARS-CoV-2 RNA test results among patients who recovered from COVID-19 with prior negative results. JAMA Intern Med. 2021;181:702&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662488</ArticleId><ArticleId IdType="pubmed">33180119</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang &#xa0;SE, Feng &#xa0;A, Meng &#xa0;W, et al. &#xa0;New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen &#xa0;Z, Xiao &#xa0;Y, Kang &#xa0;L, et al. &#xa0;Genomic diversity of severe acute respiratory syndrome-coronavirus 2 in patients with coronavirus disease 2019. Clin Infect Dis. 2020;71:713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108196</ArticleId><ArticleId IdType="pubmed">32129843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen &#xa0;T, Song &#xa0;J, Liu &#xa0;H, et al. &#xa0;Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Mart&#xed;nez &#xa0;FJ, Moreno-Artero &#xa0;E, Jahnke &#xa0;S. SARS-CoV-2 and EBV coinfection. Med Clin. 2020;155:319&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486856</ArticleId><ArticleId IdType="pubmed">32953993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata &#xa0;AF, Cheng &#xa0;C-A, Desjardins &#xa0;M, et al. &#xa0;Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis. 2022;74:715&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulter &#xa0;G, Steen &#xa0;C, De Keyser &#xa0;J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 1999;30:1538&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">10436097</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown &#xa0;EP, Licht &#xa0;AF, Dugast &#xa0;A-S, et al. &#xa0;High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods. 2012;386:117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3475184</ArticleId><ArticleId IdType="pubmed">23023091</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman &#xa0;ME, Moldt &#xa0;B, Wyatt &#xa0;RT, et al. &#xa0;A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366:8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050993</ArticleId><ArticleId IdType="pubmed">21192942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischinger &#xa0;S, Fallon &#xa0;JK, Michell &#xa0;AR, et al. &#xa0;A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J Immunol Methods. 2019;473:112630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6722412</ArticleId><ArticleId IdType="pubmed">31301278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennewein &#xa0;M, Goldfarb &#xa0;I, Dolatshahi &#xa0;S, et al. &#xa0;Fc glycan-mediated regulation of placental antibody transfer. Cell. 2019;178:202&#x2013;215.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741440</ArticleId><ArticleId IdType="pubmed">31204102</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerhuis &#xa0;JA, van Velzen &#xa0;EJJ, Hoefsloot &#xa0;HCJ, Smilde &#xa0;AK. Multivariate paired data analysis: multilevel PLSDA versus OPLSDA. Metabolomics. 2010;6:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2834771</ArticleId><ArticleId IdType="pubmed">20339442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina &#xa0;F, Catalan &#xa0;P, Rodriguez-Grande &#xa0;C, et al. &#xa0;Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis. 2022;22:211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini &#xa0;E, Corsetti &#xa0;G, Romano &#xa0;C, et al. &#xa0;Serum metabolic profile in patients with long-COVID (PASC) syndrome: clinical implications. Front Med. 2021;8:714426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8339407</ArticleId><ArticleId IdType="pubmed">34368201</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar &#xa0;M, Artime &#xa0;A, Pariente &#xa0;E, et al. &#xa0;Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38:901&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Alejo &#xa0;JL, Mitchell &#xa0;J, Chang &#xa0;A, et al. &#xa0;Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA. 2022;327:1085&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814952</ArticleId><ArticleId IdType="pubmed">35113143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;A, Stacey &#xa0;HD, Mullarkey &#xa0;CE, Miller &#xa0;MS. Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202:335&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">30617114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper &#xa0;PR, Ciambrone &#xa0;GJ, Kliwinski &#xa0;CM, et al. &#xa0;Efflux of monoclonal antibodies from rat brain by neonatal fc receptor, FcRn. Brain Res. 2013;1534:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23978455</ArticleId></ArticleIdList></Reference><Reference><Citation>Atyeo &#xa0;C, Pullen &#xa0;KM, Bordt &#xa0;EA, et al. &#xa0;Compromised SARS-CoV-2-specific placental antibody transfer. Cell. 2021;184:628&#x2013;642.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755577</ArticleId><ArticleId IdType="pubmed">33476549</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis &#xa0;HE, Assaf &#xa0;GS, McCorkell &#xa0;L, et al. &#xa0;Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; &#xa0;C, Willscher &#xa0;E, Paschold &#xa0;L, et al. &#xa0;The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Reports Med. 2022;3:100663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Green &#xa0;AM, Souquette &#xa0;A, Agrawal &#xa0;M, et al. &#xa0;Longitudinal plasma cytokine profiles differentiating COVID-19 severity groups. Open forum Infect Dis. 2021;8(Suppl 1):S320&#x2013;S320.</Citation></Reference><Reference><Citation>Queiroz &#xa0;MAF, das Neves &#xa0;PFM, Lima &#xa0;SS, et al. &#xa0;Cytokine profiles associated with acute COVID-19 and long COVID-19 syndrome. Front Cell Infect Microbiol. 2022;12:931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Su &#xa0;Y, Yuan &#xa0;D, Chen &#xa0;DG, et al. &#xa0;Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski &#xa0;C, Mardin &#xa0;C, Lucio &#xa0;M, et al. &#xa0;Long COVID: association of functional autoantibodies against G-protein-coupled receptors with an impaired retinal microcirculation. Int J Mol Sci. 2022;23:7209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas &#xa0;M, Rodr&#xed;guez &#xa0;Y, Acosta-Ampudia &#xa0;Y, et al. &#xa0;Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Destras &#xa0;G, Bal &#xa0;A, Escuret &#xa0;V, et al. &#xa0;Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic. Lancet Microbe. 2020;1:e149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289579</ArticleId><ArticleId IdType="pubmed">32835345</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukerji &#xa0;SS, Solomon &#xa0;IH. What can we learn from brain autopsies in COVID-19? &#xa0;Neurosci Lett. 2021;742:135528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687409</ArticleId><ArticleId IdType="pubmed">33248159</ArticleId></ArticleIdList></Reference><Reference><Citation>Song &#xa0;E, Bartley &#xa0;CM, Chow &#xa0;RD, et al. &#xa0;Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Reports Med. 2021;2:100288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos &#xa0;H, Magira &#xa0;E, Bitzogli &#xa0;K, et al. &#xa0;Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020;7:e893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577546</ArticleId><ArticleId IdType="pubmed">32978291</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlachetzki &#xa0;F, Zhu &#xa0;C, Pardridge &#xa0;WM. Expression of the neonatal fc receptor (FcRn) at the blood-brain barrier. J Neurochem. 2002;81:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">12067234</ArticleId></ArticleIdList></Reference><Reference><Citation>Claypool &#xa0;SM, Dickinson &#xa0;BL, Wagner &#xa0;JS, et al. &#xa0;Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane fcgamma-receptor. Mol Biol Cell. 2004;15:1746&#x2013;1759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379272</ArticleId><ArticleId IdType="pubmed">14767057</ArticleId></ArticleIdList></Reference><Reference><Citation>Spatola &#xa0;M, Loos &#xa0;C, Cizmeci &#xa0;D, et al. &#xa0;Functional compartmentalization of antibodies in the central nervous system during chronic HIV infection. J Infect Dis. 2022;226:738&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9441210</ArticleId><ArticleId IdType="pubmed">35417540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco &#xa0;M, Hyrich &#xa0;KL, Al-Adely &#xa0;S, et al. &#xa0;Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79:859&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowill &#xa0;AE, de Campos-Lima &#xa0;PO. Immune response resetting as a novel strategy to overcome SARS-CoV-2-induced cytokine storm. J Immunol. 2020;205:2566&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pubmed">32958687</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta &#xa0;S, Leaf &#xa0;DE. Tocilizumab in COVID-19: some clarity amid controversy. Lancet. 2021;397:1599&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084409</ArticleId><ArticleId IdType="pubmed">33933194</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues &#xa0;RB, de Leite &#xa0;FBVM, Senne &#xa0;C. Cerebrospinal fluid analysis in patients with COVID-19-associated central nervous system manifestations: a systematic review. Arq Neuropsiquiatr. 2022;80:296&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648929</ArticleId><ArticleId IdType="pubmed">35239818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto &#xa0;A, Masciocchi &#xa0;S, Volonghi &#xa0;I, et al. &#xa0;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021;73:e3019&#x2013;e3026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799260</ArticleId><ArticleId IdType="pubmed">33395482</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar &#xa0;J, N&#xe4;&#xe4;s &#xa0;A, F&#xe4;llmar &#xa0;D, et al. &#xa0;Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2021;28:3324&#x2013;3331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham &#xa0;JL, Virhammar &#xa0;J, R&#xf6;nnberg &#xa0;B, et al. &#xa0;Antibody responses to severe acute respiratory syndrome coronavirus 2 in the Serum and cerebrospinal fluid of patients with coronavirus disease 2019 and neurological symptoms. J Infect Dis. 2022;225:965&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083780</ArticleId><ArticleId IdType="pubmed">33744954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas &#xa0;JMJ, Koo &#xa0;J-H, Lin &#xa0;Y-C, et al. &#xa0;Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. Immunity. 2022;55:1856&#x2013;1871.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350677</ArticleId><ArticleId IdType="pubmed">35987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden &#xa0;A, Grahn &#xa0;A, Bremel &#xa0;D, et al. &#xa0;Viral antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms. JAMA Netw Open. 2022;5:e2213253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127556</ArticleId><ArticleId IdType="pubmed">35604688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>